Your premier partner offering two automated single B cell antibody discovery platforms
GENOVAC now offers two highly automated and robust single B cell platforms. The BEACON® Optofluidic platform and the GENOVAC Nano platform, are enabling vastly superior high-throughput screening of the natural antibody repertoire of an immunized animal. This state-of-the-art approach significantly increases the chances for the discovery of rare functional antibodies against challenging targets like GPCRs and ion channels and reduces the total development timeline by six to 10 weeks.
The BEACON platform, created by Berkeley Lights, Inc, is uniquely designed to carefully and specifically isolate, monitor and assay almost any cell type. When used for antibody discovery, it can isolate and identify functional antibody-producing plasma B-cells in less than one day, eliminating weeks of work.
Once individual antibody-producing cells are identified they can be exported for cDNA generation through single cell RT PCR and subsequent cloning and sequencing of the immunoglobulin heavy- and light-chain variable-region (VH and VL) genes of single B-cells that express defined V genes. Each cell is tracked so that the phenotype can be linked to the genotype. Up to 10,000 individual plasma B cells can be screened for target-specificity, cross-reactivity, or cell-based functional assay utilizing our fully automated BEACON platform.
The GENOVAC Nano platform, is another automated high-throughput single B cell platform. While cross-reactivity or functional assays cannot currently be performed on this platform; the great advantage is it can test and isolate up to 100,000 individual B cells for target specificity.
GENOVAC is uniquely positioned to offer clients two robust and highly automated single B cell antibody discovery platforms. These platforms can be used either on their own or in combination to optimize the likelihood of antibody discovery even on the most difficult target antigens, such as ion channels or GPCR.
Advantages – GENOVAC Single B cell technology
Reduced total development timeline eliminates weeks of work
Screening of a much higher percentage of the immune repertoire greatly increases the chances of finding a rare antibody
Cell-based assays allow native conformation recognition for many target types
No inefficient B cell immortalization required
Advantages – BEACON platform
Allows functional single-cell assays for the discovery of specific and functional therapeutic antibodies
Allows parallel screening for species cross-reactive antibodies
Advantages – GENOVAC Nano platform
Allows screening of up to 100,000 plasma cells which constitutes the complete immune repertoire of five mice